RecruitingNCT07039604

Real-World Study of PADN for the Treatment of PAH

Real-World Study of Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Arterial Hypertension (PAH)


Sponsor

Pulnovo Medical (Wuxi) Co., Ltd.

Enrollment

200 participants

Start Date

Mar 19, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Real-World Study of PADN for the Treatment of PAH


Eligibility

Plain Language Summary

Simplified for easier understanding

This real-world study tracks outcomes in patients with pulmonary arterial hypertension (PAH) — dangerously high blood pressure in the lung arteries — who have received a procedure called pulmonary artery denervation (PADN), which uses heat or cold to disrupt nerve signals in the artery. **You may be eligible if...** - You have been diagnosed with pulmonary arterial hypertension - You received the PADN procedure since March 2024 - You are able to provide informed consent - You are willing to attend follow-up appointments **You may NOT be eligible if...** - You have contraindications to the PADN procedure - You are unable to comply with follow-up requirements - There are no other specific exclusion criteria listed Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEEnhancor™ Radiofrequency Catheter, Pulnovo Medical (Wuxi) CO., Ltd., Wuxi, Jiangsu, China

PADN: Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA. The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 # for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA. For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician.


Locations(1)

The First Affiliated Hospital with Nanjing Medical University

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07039604


Related Trials